Bayer HealthCare Pharmaceuticals Inc. and Teva Pharmaceuticals USA have agreed to pause their patent infringement case over Bayer’s Nexavar cancer drug until a similar case can be resolved in Delaware federal court.
On Wednesday, both parties asked U.S. District Chief Judge Leonard P. Stark of the District of Delaware to stay the 6-month-old case in favor of Bayer’s first-filed, consolidated litigation against Mylan Pharmaceuticals Inc. In both cases, Bayer is seeking to stop the companies from developing generic versions of Nexavar, which is used to treat kidney, liver and thyroid cancer.
